Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
Shattuck Labs (NASDAQ: STTK) announced it will present a poster on its innovative bispecific Gamma Delta T Cell Engager (GADLEN) platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022, in Boston. The presentation, titled "Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity," will feature insights from Dr. Suresh de Silva and Dr. Derek Franklin. Shattuck is focused on developing novel biologic therapies for cancer and autoimmune diseases, leveraging its proprietary ARC® platform.
- Presentation at a prestigious oncology conference highlights Shattuck's innovative GADLEN platform.
- Ongoing evaluation of SL-172154 and SL-279252 in multiple Phase 1 trials indicates active development pipeline.
- None.
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC’s 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston.
Presentation Details
Abstract Title: Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity
Abstract Number: 1203
Presenters: Suresh de Silva, Ph.D., Vice President of Product Development at Shattuck Labs and Derek Franklin, Ph.D., Scientist III at Shattuck Labs
Date: November 10th
Location: Boston, MA
Poster Hall Hours: 9:00 a.m. to 9:00 p.m. ET
Further information about the Society for Immunotherapy of Cancer Meeting can be found at:
https://www.sitcancer.org/2022/home
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What is Shattuck Labs presenting at the SITC Annual Meeting?
When will Shattuck Labs present its findings at the SITC Annual Meeting?
What are the key components of Shattuck Labs' therapeutic pipeline?
What is the significance of the GADLEN platform for Shattuck Labs?
